India's data centre sector draws $15 billion since 2020, set to add $20-$25 billion by 2030: Report
AI-image
NEW DELHI: India's data centre (DC) sector attracted investments totalling approximately $15 billion since 2020 and is expected to witness an additional $20–25 billion in funding over the next six years, according to a report by real estate consultancy Colliers.
Driven by a surge in cloud computing, artificial intelligence adoption, and digital transformation, India's data centre capacity across seven major cities has reached 1,263 MW as of April 2025. This figure is projected to more than triple, surpassing 4,500 MW by 2030.
Currently, the total DC footprint occupies 15.9 million square feet of real estate, which is anticipated to expand dramatically to around 55 million square feet within the same period.
'The scale-up in the Indian DC industry has been accompanied by equally impressive investments in the last 5–6 years. These have primarily focused on land acquisition, construction, and infrastructure development,' said the Colliers report, quoted by PTI.
The data encompasses co-location data centres located in key cities including Bengaluru, Chennai, Delhi NCR, Hyderabad, Kolkata, Mumbai, and Pune, and considers both occupied and unoccupied IT load capacity.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
2025 Top Trending local enterprise accounting software [Click Here]
Esseps
Learn More
Undo
'India is becoming a global data centre hotspot, fuelled by rapid digitalisation, data localisation norms, and strong government support. As this growth trajectory continues, India's DC capacity is expected to exceed 4,500 MW in the next 5–6 years,' said Jatin Shah, chief operating officer, Colliers India.
He added that India's strategic advantages- such as the availability of land, dependable power infrastructure, and a skilled workforce- are helping the country emerge as a leading data centre hub in the Asia-Pacific (APAC) region.
Shah also noted the growing role of edge data centres in the market, highlighting the shift beyond large-scale colocation and hyperscaler facilities. 'This trend is driven by the need for lower latency, real-time data processing, improved application performance, and greater business agility,' he said.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Housing sales decline 20% in India, 25% in MMR
Mumbai: Increasing property prices and geopolitical tensions across the world have hit housing sales in seven metropolitan cities in India, with sales dropping by 20% in the second quarter of 2025 compared to the second quarter of 2024. The Mumbai Metropolitan Region (MMR) was hit the hardest, with housing sales dropping by 25%, from 41,540 units in the second quarter of 2024 to 31,275 units in the second quarter of 2025, according to a report by real estate consulting firm, Anarock. (Hindustan Times) Approximately 96,285 houses were sold in the second quarter (April-June) of 2025 across the seven metropolitan cities – National Capital Region, MMR, Bengaluru, Pune, Hyderabad, Chennai and Kolkata, compared to 120,335 houses sold in the same period in 2024. Housing sales in the seven cities increased marginally by 3% compared to the first quarter of 2025, the report shows. Chennai, the National Capital Region (NCR), Hyderabad and Bengaluru witnessed a spike in sales by 40%, 14%, 9% and 1% respectively. But in Kolkata, Pune and the MMR, housing sales dropped by 10%, 4% and 1%, respectively. 'The second quarter of 2025 was a rollercoaster for the Indian housing market, rocked by major military actions at home and abroad. The war-like climate pushed homebuyers into wait and watch mode, compounding the impact of soaring property prices over the past two years,' Anuj Puri, chairman, Anarock Group, told Hindustan Times. 'Now, with domestic tensions easing and the Reserve Bank of India's repo rate cut injecting fresh optimism, buyer sentiment is rebounding.' Similar sentiments were shared by other real estate consultants. 'Geopolitical tensions always have an impact on Indian real estate, though the degree varies depending on the geography and Indian economic interests in those countries,' said a real estate consultant, requesting anonymity. 'This time around, with America intervening in the Iran-Israel war, people feared that a medium to large-scale conflict may lead to economic slowdown or job cuts. Hence, home hunters decided to keep their purchase decisions on hold.' In keeping with the dip in sales, new launches decelerated by 16% on a year-on-year basis, from approximately 117,165 units in the second quarter of 2024 to around 98,625 units in the second quarter of 2025. Realty hotspots MMR and NCR saw the maximum new supply, accounting for 48% of the total new supply across the seven cities. MMR witnessed a 36% yearly decline and a 8% quarterly decline in new supply. One of the top developers in the MMR, who recently launched a project in the extended Navi Mumbai area, said, 'When the Ukraine-Russia conflict broke out in February 2022, we thought it would last only a few weeks, but we have been proved wrong. But that conflict did not have as much impact on India's realty industry as the one in the Middle East, especially with America's involvement.' Puri was optimistic about an uptick in sales in forthcoming quarters. 'Despite a 20% year-on-year dip in sales across the top seven cities, a 3% uptick this quarter signals renewed momentum,' he said. 'With home loan rates softening and developers largely holding prices steady, the stage is set for a potential upswing in housing sales in the coming quarters.'
Time of India
an hour ago
- Time of India
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger deal was announced following a marathon meeting of Torrent Pharma's board of directors on against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
Time of India
an hour ago
- Time of India
Torrent Pharma to Acquire JB Chemicals at ₹25k cr Valuation
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of ₹25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the time. With the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger details. The deal was announced following a marathon meeting of Torrent Pharma's board of directors on Sunday. That's against the stock's Friday close of ₹1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow a merger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in 2020. Torrent Pharma posted FY25 revenue of ₹ 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous year. Over the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. A press statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person added. The company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.' For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Infinx. JB Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
